Clinical Trials Logo

Clinical Trial Summary

The Perceval sutureless aortic bioprosthesis is a bovine pericardium valve mounted in a nitinol stent that can be compressed and positioned in a valve delivery system. Similarly, to transcatheter aortic valve implantation (TAVI) devices, the anchoring and good sealing of the Perceval bioprosthesis relies on oversizing by design of the nitinol stent compared with the native aortic annulus. With the advent of TAVI, cardiac computed tomography (CT) has become the gold standard technique for measuring the aortic annulus in patients undergoing transcatheter procedures, and the CT-derived axial image of the aortic virtual basal ring (VBR) is considered as the reference for sizing by most of the manufacturers of transcatheter valves . Interestingly, the VBR lies exactly on the plane passing through the nadir of the 3 aortic cusps, that is where, according to the instructions for use, a correctly positioned Perceval valve should be deployed. VBR could then provide a good estimate of the annular dimension for the Perceval pre-operative sizing.


Clinical Trial Description

Recent evidence in TAVI patients suggests that significant underexpansion or distortion of valved stents may be associated with altered leaflet function, leading to increased transprosthetic gradients and possibly predisposing to other negative outcomes such as valve thrombosis, low platelet counts, thromboembolic events, and early degeneration . Moreover, there is evidence that excessive oversizing of the Perceval valve is detrimental. The present study is aimed to investigate the relationship between the CT-derived measure of the annulus dimension and early hemodynamic and clinical outcomes in patients undergoing sutureless aortic valve replacement (AVR) with the Perceval sutureless aortic valve and define the Perceval sizing chart based on preoperative CT-scan measurements. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05799573
Study type Observational
Source Maria Cecilia Hospital
Contact Elisa Mikus, MD
Phone 0545/217678
Email emikus@gvmnet.it
Status Recruiting
Phase
Start date December 1, 2022
Completion date December 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05438862 - Early Aortic vaLve surgEry Versus wAtchful waitiNg Strategy in Severe Asymptomatic aOrtic reguRgitation N/A
Completed NCT03644784 - Protocoled Quantitative Assessment of Aortic Regurgitation Using Videodensitometry in a Multicontinental Trial in Rotterdam, Montreal, Yamaguchi, Segeberg, Amsterdam.
Recruiting NCT06381271 - Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation
Recruiting NCT04797572 - Clinical Evaluation of the Free Margin Cusp Sizer (CALIBRATE) N/A
Not yet recruiting NCT05536310 - TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease
Completed NCT02375282 - Physical and Functional Recovery From Cardiac Surgery in Hospitalized Patients: A Feasibility Pilot Study N/A
Completed NCT04548726 - Hemodynamic Matched Comparison of the Balloon-Expandable Transcatheter Heart Valves Myval and Sapien-3 for the Treatment of Aortic Stenosis
Completed NCT01593917 - Trifectaâ„¢ Long Term Follow-Up (LTFU) Study
Recruiting NCT05459233 - Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR N/A
Recruiting NCT05902897 - Aortic or Mitral Valve Replacement With the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis
Completed NCT03807921 - Anticoagulation for Aortic Bioprosthesis (ANTIPRO) Phase 4
Recruiting NCT04464655 - A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
Completed NCT00636987 - Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra N/A